Actively Recruiting
A Study of EOC237 in Patients With Advanced Solid Tumor
Led by Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd · Updated on 2023-11-02
48
Participants Needed
1
Research Sites
166 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.
CONDITIONS
Official Title
A Study of EOC237 in Patients With Advanced Solid Tumor
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Advanced solid tumors for which standard curative or palliative treatments do not exist or are no longer effective
- Expected survival of at least 3 months
- ECOG performance status of 0 or 1
- Good organ and marrow function
You will not qualify if you...
- History of severe drug allergic reaction
- Pregnant or breastfeeding female subjects
- Uncontrolled, significant intercurrent or recent illness
- Corrected QT interval (QTcF) greater than 480 ms on ECG
- Use of certain concomitant medications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China, 100029
Actively Recruiting
Research Team
B
Binghe Xu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here